<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: To determine whether serum <z:chebi fb="3" ids="27226">uric acid</z:chebi>: (1) is associated with <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) <z:hpo ids='HP_0011420'>death</z:hpo> and/or <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>; and (2) consistent with published data, predicts these outcomes in older patients and those of southern European ethnicity </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We studied those 1,268 (98%) of 1,294 type 2 participants in the observational Fremantle <z:mp ids='MP_0002055'>Diabetes</z:mp> Study who had a fasting serum <z:chebi fb="3" ids="27226">uric acid</z:chebi> measured at baseline </plain></SENT>
<SENT sid="2" pm="."><plain>Mortality data were collected over a mean (+/-SD) 10.3 +/- 3.9 years </plain></SENT>
<SENT sid="3" pm="."><plain>Cox proportional hazards modelling was used to determine independent baseline predictors of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and <z:hpo ids='HP_0000001'>all</z:hpo>-cause <z:hpo ids='HP_0011420'>death</z:hpo> including fasting serum <z:chebi fb="3" ids="27226">uric acid</z:chebi> as a continuous variable and quartiles </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: During follow up, 525 <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred (41.4% of the cohort) of which 271 (51.6%) were attributed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In univariate analyses, patients in the highest <z:chebi fb="3" ids="27226">uric acid</z:chebi> quartile had the greatest <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality (p = 0.007 and p = 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>After adjustment for significant variables in the most parsimonious model, baseline serum <z:chebi fb="3" ids="27226">uric acid</z:chebi> was not an independent associate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> or <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality whether entered as a continuous variable (HR 1.11 [95% CI 0.96-1.27] and 1.10 [95% CI 0.98-1.22] for a 0.1 mmol/l increase, respectively) or as quartiles (p &gt; 0.10) </plain></SENT>
<SENT sid="7" pm="."><plain>Analyses of 638 patients &gt;65 years of age and 231 of southern European ethnicity produced similar results </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: Serum <z:chebi fb="3" ids="27226">uric acid</z:chebi> was not an independent predictor of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> or <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality in our community-based type 2 patients </plain></SENT>
<SENT sid="9" pm="."><plain>Fasting serum <z:chebi fb="3" ids="27226">uric acid</z:chebi> concentrations do not appear to be prognostically useful in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>